Devices in Heart Failure Patients—Who Benefits From ICD and CRT?

Alexander Breitenstein* and Jan Steffel

Electrophysiology, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland

Despite advances in heart failure treatment, this condition remains a relevant medical issue and is associated with a high morbidity and mortality. The cause of death in patients suffering from heart failure is not only a result of hemodynamic failure, but can also be due to ventricular arrhythmias. Implantable cardioverter defibrillators (ICDs) are these days the only tool to significantly reduce arrhythmic sudden death; but not all patients benefit to the same extend. In addition, cardiac resynchronization therapy (CRT) is another tool which is used in patients suffering from heart failure. Even though both devices have been investigated in large randomized trials, both ICD and CRT remain underutilized in many countries. This brief review focuses on various aspects in this regard including a short overview on upcoming device novelties in the near future.

Keywords: heart failure, cardiac resynchronization, implantable cardioverter defibrillator, subcutaneous ICD (S-ICD), imaging

INTRODUCTION

According to current ESC guidelines, heart failure can be separated into heart failure with preserved ejection fraction (LVEF > 50%; HFpEF), mid-range EF (LVEF 40–49%; HFmrEF) and reduced ejection fraction (LVEF < 40%; HFrEF) (1). The cause of death in patients suffering from heart failure is not only a result of hemodynamic failure but also suddenly and unexpectedly occurring from ventricular electrical disturbances such as ventricular tachycardia and -fibrillation. Implantable cardioverter defibrillators (ICDs) represent the only available tool in our treatment armamentarium proven to prevent arrhythmic sudden cardiac death. In addition, cardiac resynchronization therapy (CRT) is an established treatment option significantly improving both quality of life as well as mortality.

In spite of these proven benefits, both ICD as well as CRT therapy remain underutilized in many countries (2). The reasons are manifold. This brief review focusses on some of the most important aspects in this regard, including continuing medical education regarding the pathophysiology, epidemiology, clinical trial results as well as novel technologies, which are paramount to allow for optimal dissemination of these important therapies and to reduce morbidity and mortality in this fragile patient population.
IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) THERAPY IN PATIENTS SUFFERING FROM CHRONIC HEART FAILURE (CHF)—OF PRIMARY AND SECONDARY PREVENTION, IN ISCHEMIC AND NON-ISCHEMIC CARDIOMYOPATHY

Patients with heart failure and reduced ejection fraction (LVEF < 35%) are at an increased risk of sudden cardiac death due to ventricular arrhythmias. This risk is highest in those who already suffered from previous ventricular arrhythmic events (3). In this “secondary prevention” situation where no reversible cause such as an acute myocardial infarction can be identified, an ICD is recommended with a class IA indication (if survival > 1 year with good functional status is predicted) according to ESC guidelines (1) (Table 1).

The situation is more complex in primary prevention. Even though current guidelines recommend the implantation of an ICD in patients suffering from heart failure with an LVEF ≤ 35% despite at least 3 months of optimal medical treatment, a NYHA class II-IIa and a predicted survival of > 1 year, there seems to be a discrepancy of the beneficial effect of an ICD depending on the underlying heart disease. Indeed, patients with ischemic heart disease have a class IA indication, while in the non-ischemic population the indication level is IB (Table 1). Two large trials investigated the role of an ICD in the primary prevention context: The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) (4) and the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) (5). Both trials demonstrated a mortality benefit in patients with severely reduced LVEF (≤ 30% in the MADIT-II trial, ≤ 35% in SCD-HeFT). In MADIT-II, which enrolled patients with ischemic heart disease and a previous myocardial infarction, the ICD offered a relative mortality reduction of 31% over 5 years. SCD-HeFT on the other hand recruited a mixed population of ischemic and non-ischemic cardiomyopathy. Subgroup analyses did not show a difference in the outcome of total mortality reduction between ischemic and non-ischemic heart disease indicating a similar effect in both patient population. In contrast, the more recent randomized Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH) trial investigated the role of primary prevention ICDs exclusively in non-ischemic cardiomyopathy; it demonstrated a significant reduction in sudden cardiac death in patients with non-ischemic heart disease with an LVEF ≤ 35%—but without an effect on all-cause mortality, the predefined primary endpoint (6).

How do these results fit together? Do we need to rethink the indication for primary prevention ICD implantation in the entire non-ischemic population? Even though a recent survey of the European Heart Rhythm Association (EHRA) has shown that already 4 months after the publication of the DANISH trial, nearly 50% of physicians changed their current practice in recommending an ICD implantation in a non-ischemic cardiomyopathy patient (7), a meta-analysis has shown a benefit of primary prevention ICDs even regarding total mortality (8). What to do in light of these controversial data? Rather than jumping to conclusions and withholding an ICD on a general basis in this population, it may be worthwhile to take a look at the data in a little bit more detail. Indeed, improving patient selection in non-ischemic heart disease may be the way to go to maximize the benefit of ICD therapy. Subgroup analyses of the DANISH trial have shown that younger patients with an age of < 70 years or those with less severe heart failure (as indicated by lower NT-proBNP levels) indeed demonstrated a reduction in all-cause mortality (6, 9). These data imply that using just the LVEF alone to predict whether an individual patient will more likely die from pump failure vs. ventricular arrhythmias (10–12) may be insufficient. On a more general level, these results further indicate that our current way of risk-stratification is insufficient and that a more refined way of looking at things is warranted. The Seattle Heart Failure Model, for example, incorporates various risk factors including age as well as laboratory parameters to predict mortality in heart failure patients, and may represent an attractive model for patient selection for an ICD. Another promising strategy is to assess the potential proarrhythmogenic myocardial substrate. Late gadolinium enhancement (LGE) on cardiac MRI corresponds to areas of myocardial fibrosis (13), and reports have shown that patients with LGE exert a higher risk for sudden cardiac death and ventricular arrhythmias (14). Especially mid-wall LGE was associated with a substantial nine-fold increase in the rate of sudden cardiac death/aborted sudden cardiac death in patients with dilated cardiomyopathy and a LVEF ≥ 40% (15). In addition to CMRI, electroanatomical mapping (EAM) is a currently widespread way of invasively investigating myocardial scaring (Figure 1). By measuring local

---

**TABLE 1 | Current ICD and CRT indications according to the ESC guidelines.**

| Indication | Class |
|------------|-------|
| Secondary prevention | |
| In patients with documented VF or haemodynamically not tolerated VT | IA |
| Absence of reversible causes or within 48h after myocardial infarction | |
| Reasonable expectation of survival with a good functional status > 1 year | |
| Severe impaired LV function (< 35%) | |
| With NYHA II-IIa | |
| Despite optimal medical treatment for ≥ 3 months | |
| Ischemic cardiomyopathy | IA |
| Non-ischemic cardiomyopathy | IB |
| Primary prevention | |
| | |
| | |
| Indication | Class |
| CRT | |
| Severely impaired LV function (< 35%) | |
| NYHA II-IIa | |
| Despite optimal medical treatment for ≥ 3 months | |
| With LBBB and QRS duration > 150 ms | IA |
| With LBBB and QRS duration 130-149 ms | IB |
| With non-LBBB and QRS duration > 150 ms | IIa |
| With non-LBBB and QRS duration 130-149 ms | IIb |
| With LBBB and QRS duration < 130 ms | IA |
| With non-LBBB and QRS duration ≤ 120 ms | IB |

---
electrical properties in the context of an electrophysiological study, areas of scar tissue can be differentiated from healthy myocardium (16). Even though both imaging modalities display great promise, their value needs to be prospectively tested in randomized trials. In addition to imaging modalities, various other markers of increased arrhythmia risk can potentially be incorporated in the ICD decision making process such as genetic testing, circulating biomarkers, non-invasive electrophysiological testing etc.

On the other hand, it needs to be kept in mind that the reduction in sudden cardiac death from an ICD in this population not translating into a total-mortality benefit may not only be because of an excess in non-arrhythmogenic deaths—it may also be due to complications and morbidity of the device itself. Therefore, further investigations and developments in improving device technology are essential. The subcutaneous implantable cardioverter defibrillator (S-ICD) represents a novel model of an ICD designed to reduce the occurrence as well as the associated morbidity (and mortality) of one of the most relevant lifetime risks of transvenous device systems: infection. The generator in a S-ICD is located at the left lateral chest in the space between the anterior serratus and the latissimus dorsi muscles. The lead is tunneled within the subcutaneous tissue toward the xiphoid process and from advanced alongside the sternum cranially (Figure 2). Large randomized trials are on its way, but registries are very promising with lower lead complications and a higher lead survival over time in the SICD population (17). As such, recent ESC guidelines recommend a subcutaneous ICD with a class IIa indication as an alternative to transvenous ICDs in the absence of contraindication (18). A subcutaneous defibrillator is not suitable if patients are in need for bradycardia pacing or cardiac resynchronization as well as overdrive pacing; however, the solution of most these problems, however, appears to be only a matter of time, since a combination of the S-ICD with a leadless pacemaker will enter into clinical trials in the near future. Furthermore, patients need to undergo a pre-procedure sensing vector screening to ensure adequate sensing of the QRS complex and T wave to avoid under- as well as T wave oversensing; at least one out of 3 sensing vectors needs to have appropriate sensing in a supine and sitting or standing posture.

CARDIAC RESYNCHRONISATION THERAPY (CRT)—OF “RESPONDERS” AND “NON-RESPONDERS”

Cardiac resynchronization therapy has fundamentally changed the treatment of patients suffering from heart failure. Impaired left ventricular function often results in
ventricular conduction disease, which secondarily leads
to electrical and mechanical ventricular dysynchrony
further impairing hemodynamics of the ventricle (19).
Disrupting this vicious is the goal of biventricular pacing
in CRT.

According to current guidelines, a CRT device is indicated
in patients with stable, symptomatic (NYHA II-IVa) systolic
heart failure despite 3 months of optimal medical treatment,
an LVEF ≤ 35% and a QRS duration of ≥ 130 ms (1). This
indications results from large randomized trials investigating
the role of cardiac resynchronization in patients with severely
symptomatic heart failure (mostly NYHA III) and a QRS
duration of ≥ 120 ms: The Comparison of Medical Therapy,
Pacing, and Defibrillation in Heart Failure (COMPANION) (20)
and the Cardiac Resynchronisation-Heart Failure (CARE-HF)
(21) trial. Both studies have demonstrated that biventricular
stimulation in this population reduced total mortality up to
36%, which was later confirmed by registry data and meta-
analyses (22–24). Subsequently, the benefit of CRT has been
extended to patients with mild heart failure symptoms (NYHA
II). In the Multicenter Automatic Defibrillator Implantation
Trial with Cardiac Resynchronization Therapy (MADIT-CRT),
heart failure patients with LVEF ≤ 30% and NYHA I-II as
well as a QRS duration of > 130 ms were enrolled (25). Total
mortality in the CRT group was 34% lower as compared to
only medically treated patients. This finding is support by data
from the Resynchronization-Defibrillation for Ambulatory Heart
Failure (RAFT) trial, which has shown in patients with LVEF of
≤ 30%, a QRS duration of > 120 ms and NYHA II-III that CRT
reduces total mortality by 25% (26).

In spite of these impressive results, a couple of aspects in the
context of CRT need to be discussed:

1. From the MADIT-CRT and RAFT trials, there is insufficient
data to recommend a CRT in patients with NYHA
class I (25, 26).
2. Even though a CRT device reduces mortality in correctly
selected patients, it has no benefit and may cause harm
if implanted in the wrong patients. The EchoCRT trial
demonstrated no benefit and a signal for increased mortality
if a CRT device is implanted in patients with a narrow
QRS complex (despite mechanical ventricular dyssynchrony
as assessed by echocardiography) (27).
3. Guidelines judge a CRT device implantation in patients with a
LBBB with class I indication (IA if QRS width if > 150 ms, IB
if QRS duration is 130–149 ms), whereas non-LBBB situations
get a class II indication. Patients with LBBB indeed seem
to have a more severe type of LV electrical dyssynchrony
as compared to non-LBBB situation (28, 29) and are likely
to benefit more from cardiac resynchronization. As such,
in the MADIT-CRT trial, a pre-defined subgroup analysis
demonstrated that only patients with LBBB derived a greater
benefit from CRT regarding heart failure event-free survival
(25, 26, 30). This finding is supported by a meta-analysis of
the above mentioned trials showing no benefit of CRT in
non-LBBB patients (24). One needs to keep in mind that none of the pivotal trials investigating the role of CRT in heart failure patients used QRS morphology as an inclusion criterion (in contrast to QRS duration).

4. Atrial fibrillation (AF) was an exclusion criterion in the vast majority of CRT trials (except for the RAFT study), even though AF and heart failure regularly co-exists and patients with AF together with heart failure exhibit a worse prognosis (31, 32). Due to fast, irregular atrioventricular conduction, AF not rarely limits the benefit of a CRT device compared to sinus rhythm (33). However, if atrial fibrillation conduction is interrupted by atrioventricular node ablation, the benefit of a CRT device—at least in non-randomized trials and meta-analysis—was shown to be similar to patients without AF (34, 35).

5. On the flip-side one needs to be aware that up to one-third of patients with a CRT device does not show a benefit over time (so-called “non-responders”; Figure 3) (37). However, there is no standard consensus on the definition of “response” and “non-response”: While some use clinical parameters (mortality, heart failure hospitalization, NYHA class) (19, 38), others use echocardiographic measurements (increase in LVEF, decrease in endsystolic volume) (39) or a combination. Not rarely, there is a discrepancy between clinical and echocardiographic responses (40). A typical example is the response of CRT in patients with ischemic heart disease. Patients with prior myocardial infarction are known to demonstrate less of an echocardiographic response/remodeling to CRT (41, 42). However, the benefit of CRT in the pivotal trials (CARE-HF and COMPANION) did not depend on the underlying heart disease (20, 21). On the contrary, since patients suffering from ischemic heart disease have a worse prognosis with a higher absolute rate of events, their absolute risk reduction may be even higher (43)—and, as a result, the “number needed to treat” even lower.

Finally, the “response” to CRT is a very relative measure. Apart from non-responders, as mentioned above, patients may stabilize their cardiac function and clinical course. We previously coined these individuals “non-progressors” (36). On a more fundamental level, the lack of visible improvement in LVEF or clinical status after CRT implantation may lead physicians to distrust CRT as a valuable way to reduce morbidity and mortality—leading to the observed lower-than-expected implementation rates (2). We tend to forget in these cases that CHF is a chronically progressive, malignant disease and stabilization of its course—sometimes over years—often incorrectly termed as “non-response” indeed indicates a significant benefit of CRT for this vulnerable patient population.

On the other side of the spectrum, some patients exhibit a huge benefit of CRT and may even normalize their LV function (so-called “super-responders”; Figure 3) (36). Every effort has to be undertaken to achieve maximum benefit from a CRT device. Even though echocardiographic assessment of ventricular dyssynchrony is not a reliable parameter to predict outcome to CRT (27, 44), pre-implantation imaging may become more important to identify optimal position for the LV lead (45–47). During the implantation, it is crucial to place the lead—if possible—at the localization with the longest electrical delay to potentially offer a higher level of resynchronization (48). Optimal device programming by experts in device follow-up and troubleshooting post-implantation and during the further course is furthermore essential to provide maximum benefit (49). Even though routinely optimizing device intervals after CRT implantation has not been shown to be of clinical benefit (50), it may be relevant in “non-responders,” negative responders and those experiencing clinical events and complications. In addition, device-based algorithms to optimize CRT response such as AdaptivCRT (51, 52) or SyncAV (53) may become more important in the near future.

In addition to biventricular pacing, other pacing techniques are under investigation which potentially may further improve the outcome in patients with heart failure. One such strategy is His-bundle pacing (HBP); indeed, HBP in the context of bradycardia indications has been shown to be a safe and successful option for patients with high burden of chronic ventricular pacing (54). The role of HBP in heart failure patients is currently investigated in various trials (HOPE-HF trial, His-SYNC trial) (55). In how far this will become a standard also outside expert centers with specific expertise remains to be proven in large outcome studies.

**CONCLUSION**

Implantable devices such as ICDs and CRTs are a cornerstone in the modern treatment of heart failure patients, reducing morbidity and mortality in this population. Continuing medical education regarding the pathophysiology, epidemiology, clinical trial results and novel technologies are of paramount importance to optimize patient selection and individual benefit. Ongoing and future studies and technological advances are aiming to improve patients’ prognosis even further. Their implementation, however, will be the task of all stakeholders involved including cardiologists,
general practitioners and—increasingly importantly—the patient him/herself. Only by a collaborative effort will we be able to move the field forward, and to further develop concepts to improve the prognosis of patients with heart failure.

REFERENCES

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Failure. (2016) 18:891–975. doi: 10.1002/ejhf.592

2. Dickstein K, Normand C, Auricchio A, Bogale N, Cleland JG, Gitt AK, et al. CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how? Eur J Heart Failure. (2018) 20:1039–51. doi: 10.1002/ejhf.1001

3. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDT studies. Arrhythmias vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. (2000) 21:2071–8. doi: 10.1053/euhj.2000.2476

4. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. (2005) 352:225–37. doi: 10.1056/NEJMoa043399

5. Moss AJ, Zareba W, Hall WJ, Klein H, Brown MW, Daubert JP, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. (2002) 346:877–83. doi: 10.1056/NEJMoa013474

6. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. (2016) 375:1221–30. doi: 10.1056/NEJMoa1608029

7. Haugaa KH, Tilz R, Bodeva S, Dobreanu D, Sciaraffia E, Mansourati J, et al. Implantable cardioverter defibrillator use for primary prevention in ischaemic and non-ischaemic heart disease-indications in the post-DANISH trial era: results of the European Heart Rhythm Association survey. Europace. (2017) 19:660–4. doi: 10.1093/eurheartj/eur089

8. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. (2004) 292:2874–9. doi: 10.1001/jama.292.23.2874

9. Elming MB, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, et al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation. (2017) 136:1772–80. doi: 10.1161/CIRCULATIONAHA.117.028829

10. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens JH, et al. Out-of-hospital cardiac arrest—the relevance of heart failure. The Maasricht Circulatory Arrest Registry. Eur Heart J. (2003) 24:1204–9. doi: 10.1016/S0195-668X(03)00191-X

11. Stecker EC, Vickers C, Waltz J, Socoteanu C, John BT, Mariani R, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol. (2006) 47:1161–6. doi: 10.1016/j.jacc.2005.11.045

12. Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT, et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation. (2009) 120:835–42. doi: 10.1161/CIRCULATIONAHA.108.816884

13. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. (2004) 43:2260–4. doi: 10.1016/j.jacc.2004.03.025

14. Kuruvilla S, Adenan N, Katwil AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imag. (2014) 7:250–8. doi: 10.1161/CIRCIMAGING.113.001144

15. Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, et al. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. (2017) 135:2106–15. doi: 10.1161/CIRCULATIONAHA.116.026910

16. Sasaki T, Miller CE, Hansford R, Zipunnikov V, Zviman MM, Marine JE, et al. Impact of nonischemic scar features on local ventricular electromgrams and scar-related ventricular tachycardia circuits in patients with nonischemic cardiomyopathy. Circ Arrhythmia Electrophysiol. (2013) 6:1139–47. doi: 10.1161/CIRCEP.113.000159

17. Brouwer TF, Vilmaz D, Lindeboom R, Buiten MS, Olde Nordkamp L, Schalij MJ, et al. Long-term clinical outcomes of subcutaneous versus transvenous implantable defibrillator therapy. J Am Coll Cardiol. (2016) 68:2047–55. doi: 10.1016/j.jacc.2016.08.044

18. Priori SG, Blomstrom-Lundqvist C. 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs. Eur Heart J. (2015) 36:2757–9. doi: 10.1093/eurheartj/ehv316

19. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al. Combined cardiac resynchronization and implantable cardioverter defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA. (2003) 289:2685–94. doi: 10.1001/jama.289.20.2685

20. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. (2004) 350:2140–50. doi: 10.1056/NEJMoa032423

21. Cleland JG, Daubert JC, Erdmann E, Freemantele N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. (2005) 352:1539–49. doi: 10.1056/NEJMoa050496

22. Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation. (2010) 122:2022–30. doi: 10.1161/CIRCULATIONAHA.110.956011

23. Gold MR, Thebault C, Linde C, Abraham WT, Gerritse B, Ghio S, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study. Circulation. (2012) 126:822–9. doi: 10.1161/CIRCULATIONAHA.112.097709

24. Cunnington C, Kwok CS, Satchithanandam DK, Patwala A, Khan MA, Zaidi A, et al. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials. Heart. (2015) 101:1456–62. doi: 10.1136/heartjnl-2014-306811

25. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. (2009) 361:1329–38. doi: 10.1056/NEJMoa0906431

26. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly SJ, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. (2010) 363:2385–95. doi: 10.1056/NEJMoa1009540

27. Ruschitzka F, Abraham WT, Singh JP, Rus J, Borer JS, Brugada J, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. (2013) 369:1395–405. doi: 10.1056/NEJMoa1306687

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
28. Haghighi M, Bagherzadeh A, Farahani MM, Haghighi ZO, Sadr-Ameli MA. Significance of QRS morphology in determining the prevalence of mechanical dyssynchrony in heart failure patients eligible for cardiac resynchronization: particular focus on patients with right bundle branch block with and without coexistent left-sided conduction defects. *Europan*. (2008) 10:566–71. doi: 10.13030/europan0084

29. Yu CM, Fung JW, Chan CK, Chan YS, Zhang Q, Lin H, et al. Comparison of efficacy of reverse remodeling and clinical improvement for relatively narrow and wide QRS complexes after cardiac resynchronization therapy for heart failure. *J Cardiovasc Electrophysiol*. (2004) 15:1058–65. doi: 10.1111/j.1540-8167.2004.03648.x

30. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, et al. Effectiveness of cardiac resynchronization therapy by qrs morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT). *Circulation*. (2011) 123:1061–72. doi: 10.1161/CIRCULATIONAHA.110.960898

31. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Cardesante in Heart Failure—Assessment of Reduction in Mortality and morbidity (CHARM) program. *J Am Coll Cardiol*. (2006) 47:1997–2004. doi: 10.1016/j.jacc.2006.01.060

32. Trulock KM, Narayan SM, Piccini JP. Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. *J Am Coll Cardiol*. (2014) 64:710–21. doi: 10.1016/j.jacc.2014.06.1169

33. Wilton SB, Leung AA, Ghali WA, Faris P, Exner DV. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. *Heart Rhythm*. (2011) 8:1088–94. doi: 10.1016/j.hrthm.2011.02.014

34. Gasparini M, Auricchio A, Metra M, Regoli F, Fanti C, Lamp B, et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. *Eur Heart J*. (2008) 29:1644–52. doi: 10.1093/eurheartj/ehn133

35. Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM, Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure: a systematic review. *J Am Coll Cardiol*. (2012) 59:719–26. doi: 10.1016/j.jacc.2011.10.891

36. Steffel J, Ruschitzka F. Superresponse to cardiac resynchronization therapy. *Circulation*. (2014) 130:87–90. doi: 10.1161/CIRCULATIONAHA.113.006124

37. Versteeg H, Schiffer AF, Widdershoven JW, Meine MM, Doevendans PA, Pedersen SS. Response to cardiac resynchronization therapy: is it time to expand the criteria? *Pacing Clin Electrophysiol*. (2009) 32:1247–56. doi: 10.1111/j.1540-8199.2009.02505.x

38. Packer M. Proposal for a new clinical end point to evaluate the efficacy of cardiac resynchronization therapy (MADIT-CRT). *Circulation*. (2011) 123:1061–72. doi: 10.1161/CIRCULATIONAHA.110.960898

39. Pitzalis MV, Iacoviello M, Romito R, Massari F, Rizzon B, Luzzi G, et al. Clinical response with adaptive CRT algorithm compared with CRT with echocardiography-guided and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. *Circulation*. (2010) 122:2660–8. doi: 10.1161/CIRCULATIONAHA.110.992552

40. Martin DO, Lemke B, Birnie D, Krum H, Lee KL, Aonuma K, et al. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. *Heart Rhythm*. (2012) 9:1807–14. doi: 10.1016/j.hrthm.2012.07.009

41. Singh JP, Abraham WT, Chung ES, Rogers T, Sambelashvili A, Coles JA Jr, et al. Clinical response with adaptive CRT algorithm compared with CRT with echocardiography-guided-optimized atrioventricular delay: a retrospective analysis of multicentre trials. *Europace*. (2013) 15:1622–8. doi: 10.1093/europace/eut107

42. Varma N, O’Donnell D, Bassiouny M, Ritter P, Pappone C, Mangual J, et al. Programming cardiac resynchronization therapy for electrical synchrony: reaching beyond left bundle branch block and left ventricular activation delay. *J Am Heart Assoc*. (2018) 7:e007489. doi: 10.1161/JAHA.117.007489

43. Abdelrahman M, Subispov FA, Beer D, Durr B, Naperkowski A, Sun H, et al. Clinical outcomes of his bundle pacing compared to conventional pacing. *J Am Coll Cardiol*. (2018) 71:2319–30. doi: 10.1016/j.jacc.2018.02.048

44. Lewis AJM, Foley P, Whinnett Z, Keene D, Chandrasekarab H. His bundle pacing: a new strategy for physiological ventricular activation. *J Am Heart Assoc*. (2019) 8:e010972. doi: 10.1161/JAHA.118.010972

Conflict of Interest Statement: AB has received consultant and/or speaker fees from Abbott, Bayer, Biosense Webster, Biotronik, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Novartis, and Spectranetics/Philips. JS has received consultant and/or speaker fees from Abbott, Amgen, AstraZeneca, Attivire, Bayer, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medscape, Medtronic, Merck/MSD, Novartis, Pfizer, Sanofi-Aventis, WebMD, and Zoll. He reports ownership of CorXL. JS has received grant support through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, and Medtronic.

Copyright © 2019 Breitenstein and Steffel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.